- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06526286
Aide à la décision clinique pour augmenter l'utilisation de médicaments pour les troubles liés à l'usage d'opioïdes
The objective of this study is to evaluate the impact of clinical decision support (CDS) in the form of an alert to identify patients who may be at risk of opioid use disorder (OUD) and a clinical care pathway helping providers treating patients with opioid use disorder. The pathway provides health care providers with information and suggestions for screening and treatment of opioid use disorder, including treatment with medications. The 2022 Centers for Disease Control and Prevention (CDC) clinical practice guideline for prescribing opioids for pain recommends providers asses for and treat opioid use disorder using approved medications for opioid use disorder (MOUD). This project will implement a passive CDS alert when a provider prescribes an opioid to a patient who may be at risk of opioid use disorder. Providers will also have link access to a clinical care pathway providing support for OUD screening and treatment. Before and after comparisons of buprenorphine (a medication used to treat opioid use disorder) prescribing by providers and outcomes of patients will be examined based on medical records data collected during routine care. The study period will be approximately 18 months.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Heather Tolle, PhD
- Numéro de téléphone: 303-724-9924
- E-mail: heather.tolle@cuanschutz.edu
Lieux d'étude
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Recrutement
- UCHealth
-
Contact:
- Heather Tolle
- Numéro de téléphone: 720-848-6777
- E-mail: heather.tolle@cuanschutz.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Residents and visitors to the state of Colorado who seek healthcare within the University of Colorado Health (UCHealth) primary care system.
La description
Inclusion Criteria:
- Primary care encounter AND
- Current opioid prescription (not buprenorphine) and Active opioid medications over the last 90 days OR
- Documented as on local Pain Registry "Does the patient fit the criteria to be included on the Pain Registry?" OR
- Has active problem list diagnosis of long-term (current) use of opiate analgesic OR
- Is taking >=90 morphine milligram equivalents (MME) per day OR
- Prior positive toxicology screen for illicit drugs OR
- Diagnosis of opioid use disorder
Exclusion Criteria:
- Active cancer diagnosis in the last 1 year
- Hospice care/palliative care order
- Sickle cell disease diagnosis
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
pre implementation period
Encounters with a high risk opioid prescription prior to intervention implementation. Providers will not see any alert. |
|
|
CDS Notification
Providers will see a clinical decision support tool within the electronic health record when treating a patient at risk for opioid use disorder to encourage the provider to use a clinical care pathway to assess for opioid use disorder and when applicable, treat opioid use disorder with buprenorphine. Smart text will also be available in the electronic health record so that the provider can easily document screening and treatment discussions with the patient. |
Clinical decision support (CDS) in the form of an electronic health record (EHR)-integrated, provider-facing notification suggesting (a) the patient may be at risk for opioid use disorder and could benefit from screening, (b) patients with opioid use disorder would benefit from treatment with buprenorphine and (c) utilization of a clinical care pathway to help treat patients with opioid use disorder with buprenorphine as suggested by the Center for Disease Control and Prevention (CDC) guidelines. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of patients at risk for opioid use disorder receiving medications for opioid use disorder
Délai: 18 months
|
The number of primary care patients identified to be at risk for opioid use disorder treatment with buprenorphine for treatment divided by the total number of patients meeting opioid use disorder criteria |
18 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Clinical decision support (CDS) acceptance rate
Délai: 18 months
|
The number of times providers accepted the clinical decision support (CDS) tool and utilized the clinical care pathway in treating opioid use disorder. |
18 months
|
|
Subsequent opioid overdose/poisoning rates
Délai: Six months after an encounter where the opioid use disorder is identified
|
The number of patients who had a diagnosis of opioid overdose or poisoning |
Six months after an encounter where the opioid use disorder is identified
|
|
Buprenorphine initiation
Délai: Six months after an encounter where the opioid use disorder is identified
|
Number of patients who filled a buprenorphine prescription after being identified at risk. |
Six months after an encounter where the opioid use disorder is identified
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Jason Hoppe, DO, University of Colorado, Denver
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 24-1188
- R61DA057610 (Subvention/contrat des NIH des États-Unis)
- 24-1188 (Autre identifiant: IRB protocol)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified data utilized in this project will be housed on the National Addiction and HIV Data Archive Program (NAHDAP) after results of the study are published.
Délai de partage IPD
Data will be provided to National Addiction and HIV Data Archive Program (NAHDAP) after study results are published in peer-reviewed journals.
Critères d'accès au partage IPD
Prior to downloading study data, the individual will have to register with the site and agree to a standard data use agreement
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .